Objective: To explore serum KL-6 level and investigate its diagnostic value in interstitial lung diseases (ILDs).Methods: Serum KL-6 level was measured using the chemiluminescent enzyme immunoassay.Statistical analysis was performed for determining the KL-6 concentration of each group.Results: KL-6 level (U/mL) in the ILD group was 1388.321±1943.116,which was higher than that in the control group, showing a significant statistical difference.ROC curve analysis based on the receiver operating characteristic curve showed the optimal cut-off value of 402.5U/mL, sensitivity of 77.4%, specificity of 93.4%, and accuracy of 89.4%; through Chi-square test with the two groups, the positive rate of KL-6 in patients with ILD was proved to be significantly higher than that in the control group.KL-6 level was 1063.00±504.757 in the idiopathic pulmonary fibrosis (IPF) group, 1346.892±1827.252 in the connective tissue disease-associated interstitial lung disease (CTD-ILD) group, 467.889±288.859 in the organizing pneumonia (OP) group, 8252.333±6050.625 in the pulmonary alveolar proteinosis (PAP) group, and 359.200±392.707 in the sarcoidosis group.The rank sum test showed that the differences were statistically significant.KL-6 level was the lowest in the sarcoidosis group, followed by that in the OP group. Conclusion:Serum KL-6 level was confirmed to be highly sensitive, specific, and accurate in the diagnosis of ILD.Subgroup analysis showed that the KL-6 level was the lowest in the sarcoidosis group, followed by that in the OP group.
No takes yet. Share an insight, caveat, or question.
Zuo et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: